Not sure how today's volume came about as good news was released in past without such impact. Nevertheless today's volume puts stock on the radar creating a wealth of opportunities
PR activity is good but does not compensate for lack of insider (esp BoD) intiative - ie no deals, no stock buys, no analyst coverage. I think PR is meant to orchestrate shareholder support for proxy. Until I see materially significant steps by BoD, I vote NO and to witthold.
While posters differ on future of company (I am personally bullish), there is near unanimous agreement about the atrocious job the board is doing. Voting NO would send a clear message. Individual shareholders own most of this company compared to the board. Lets send them a message.
Simpson has done an excellent job advancing the clinical programs and I give her credit. What she and the BoD lack (she lack of experiece, the BoD lethargy) is dealmaking ability to enhance shareholder value. I own a ton of shares and believe company may ultimately succeed. However because of these factors, I am voting against all proxy proposals with exception of accountant ratification (prop 3).
you are confusing stock price with product. the fact is we will only know in retrospect about product acceptance. share price for many small caps is reactionary rather than anticipatory. small cap capital markets are very inefficient which makes them intriguing.
My experience is to wait until they have disappointment and share price plummets. Most of the multibagger biotechs rebounded from depressed levels.
while still losing money, losses are decreasing and revenue is increasing. the bar has been set very low. i have postion and am adding on dips. my time horizon is years. in best case scenario, breakeven or small profit in Q4 and growing profits in 2016 and beyond with multibagger potential esp given very low cap and float it has history working against it but anything is possible.
not tricky. there is both huge risk and huge reward potential i believe long term reward potential is 25X the risk - ie could go to $20 long term but could also go to zero. sold my PBMD. re CLSN - i also own it and believe it has reward/risk profile similar to DCTH. Neal has been on target with DCTH and will continue to be as long as trend is bearish. imo if p2 is positive, the tide will turn in a tsunamic way.